Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:20:38.870Z.
Calculation as of: 2026-10-06T14:20:38.870Z.
Quote observation: 2026-10-06T14:20:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ce14650c18fa49a41504767bbd6ec089d5034b69e4d808542ce8aeb5b63776d1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
ALX Oncology Holdings Inc.
Market Cap
$156.77M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.15M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.53M
Price/FCF Ratio
N/A
TTM Avg
78.89
3Y Avg
78.89
5Y Avg
78.89
Market Cap
$151.58M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.23M
Price/FCF Ratio
N/A
TTM Avg
193.13
3Y Avg
193.13
5Y Avg
37.96
Market Cap
$147.54M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $156.77M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $156.15M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $157.84M | N/A | 69.31 | 47.40 | 57.04 |
| Minerva Neurosciences, Inc. (NERV)vs › | $154.53M | N/A | 78.89 | 78.89 | 78.89 |
| Codexis, Inc. (CDXS)vs › | $151.66M | N/A | 55.06 | 55.06 | 55.06 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | N/A | 193.13 | 193.13 | 37.96 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $147.21M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
